1
|
Hofman P, Calabrese F, Kern I, Adam J, Alarcão A, Alborelli I, Anton NT, Arndt A, Avdalyan A, Barberis M, Bégueret H, Bisig B, Blons H, Boström P, Brcic L, Bubanovic G, Buisson A, Caliò A, Cannone M, Carvalho L, Caumont C, Cayre A, Chalabreysse L, Chenard MP, Conde E, Copin MC, Côté JF, D'Haene N, Dai HY, de Leval L, Delongova P, Denčić-Fekete M, Fabre A, Ferenc F, Forest F, de Fraipont F, Garcia-Martos M, Gauchotte G, Geraghty R, Guerin E, Guerrero D, Hernandez S, Hurník P, Jean-Jacques B, Kashofer K, Kazdal D, Lantuejoul S, Leonce C, Lupo A, Malapelle U, Matej R, Merlin JL, Mertz KD, Morel A, Mutka A, Normanno N, Ovidiu P, Panizo A, Papotti MG, Parobkova E, Pasello G, Pauwels P, Pelosi G, Penault-Llorca F, Picot T, Piton N, Pittaro A, Planchard G, Poté N, Radonic T, Rapa I, Rappa A, Roma C, Rot M, Sabourin JC, Salmon I, Prince SS, Scarpa A, Schuuring E, Serre I, Siozopoulou V, Sizaret D, Smojver-Ježek S, Solassol J, Steinestel K, Stojšić J, Syrykh C, Timofeev S, Troncone G, Uguen A, Valmary-Degano S, Vigier A, Volante M, Wahl SGF, Stenzinger A, Ilié M. Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe. ESMO Open 2023; 8:101628. [PMID: 37713929 PMCID: PMC10594022 DOI: 10.1016/j.esmoop.2023.101628] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2023] [Revised: 06/14/2023] [Accepted: 08/02/2023] [Indexed: 09/17/2023] Open
Abstract
BACKGROUND Testing for epidermal growth factor receptor (EGFR) mutations is an essential recommendation in guidelines for metastatic non-squamous non-small-cell lung cancer, and is considered mandatory in European countries. However, in practice, challenges are often faced when carrying out routine biomarker testing, including access to testing, inadequate tissue samples and long turnaround times (TATs). MATERIALS AND METHODS To evaluate the real-world EGFR testing practices of European pathology laboratories, an online survey was set up and validated by the Pulmonary Pathology Working Group of the European Society of Pathology and distributed to 64 expert testing laboratories. The retrospective survey focussed on laboratory organisation and daily EGFR testing practice of pathologists and molecular biologists between 2018 and 2021. RESULTS TATs varied greatly both between and within countries. These discrepancies may be partly due to reflex testing practices, as 20.8% of laboratories carried out EGFR testing only at the request of the clinician. Many laboratories across Europe still favour single-test sequencing as a primary method of EGFR mutation identification; 32.7% indicated that they only used targeted techniques and 45.1% used single-gene testing followed by next-generation sequencing (NGS), depending on the case. Reported testing rates were consistent over time with no significant decrease in the number of EGFR tests carried out in 2020, despite the increased pressure faced by testing facilities during the COVID-19 pandemic. ISO 15189 accreditation was reported by 42.0% of molecular biology laboratories for single-test sequencing, and by 42.3% for NGS. 92.5% of laboratories indicated they regularly participate in an external quality assessment scheme. CONCLUSIONS These results highlight the strong heterogeneity of EGFR testing that still occurs within thoracic pathology and molecular biology laboratories across Europe. Even among expert testing facilities there is variability in testing capabilities, TAT, reflex testing practice and laboratory accreditation, stressing the need to harmonise reimbursement technologies and decision-making algorithms in Europe.
Collapse
Affiliation(s)
- P Hofman
- Laboratory of Clinical and Experimental Pathology, FHU OncoAge, Biobank Côte d'Azur BB-0033-00025, Louis Pasteur Hospital, IRCAN, Université Côte d'Azur, Nice, France.
| | - F Calabrese
- Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy
| | - I Kern
- Department of Pathology, University Clinic Golnik, Golnik, Slovenia
| | - J Adam
- Department of Pathology, Groupe Hospitalier Paris Saint-Joseph, Paris, France
| | - A Alarcão
- IAP-PM, Institute of Anatomical and Molecular Pathology, Faculty of Medicine, University of Coimbra, 3004-504 Coimbra, Portugal
| | - I Alborelli
- Department of Pathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland
| | - N T Anton
- Department of Genetics, University Hospital Bichat-Claude Bernard, Paris University, Paris, France
| | - A Arndt
- Institute of Pathology and Molecular Pathology, Bundeswehrkrankenhaus Ulm, Oberer Eselsberg 40, 89081 Ulm, Germany
| | - A Avdalyan
- Multidisciplinary Clinical Center "Kommunarka" of the Moscow Health Department, Moscow, Russia
| | - M Barberis
- Oncogenomics Unit, European Institute of Oncology (IEO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy
| | - H Bégueret
- Department of Pathology, University Hospital of Bordeaux, Hôpital Haut-Lévêque, Pessac, France
| | - B Bisig
- Institute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - H Blons
- Pharmacogenomics and Molecular Oncology Unit, Biochemistry Department, Assistance Publique-Hopitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France
| | - P Boström
- Department of Pathology, Turku University Hospital, Turku, Finland
| | - L Brcic
- Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria
| | - G Bubanovic
- Laboratory for Molecular Pathology, Department of Pathology, University of Zagreb School of Medicine and University Hospital Centre Zagreb, Zagreb, Croatia
| | - A Buisson
- Department of Biopathology, Centre Léon Bérard, Lyon, France
| | - A Caliò
- Department of Diagnostics and Public Health, Section of Pathology, University and Hospital Trust of Verona, Verona, Italy
| | - M Cannone
- Inter-Hospital Pathology Division, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), MultiMedica, Milan, Italy
| | - L Carvalho
- IAP-PM, Institute of Anatomical and Molecular Pathology, Faculty of Medicine, University of Coimbra, 3004-504 Coimbra, Portugal
| | - C Caumont
- Department of Tumor Biology, University Hospital of Bordeaux, Hospital Haut-Lévêque, Pessac, France
| | - A Cayre
- Department of Biopathology, Jean Perrin Centre, Clermont-Ferrand, France
| | - L Chalabreysse
- Department of Pathology, Groupement Hospitalier Est, Bron, France
| | - M P Chenard
- Department of Pathology, University Hospital of Strasbourg, 67098 Strasbourg, France
| | - E Conde
- Department of Pathology, 12 de Octubre University Hospital, Universidad Complutense de Madrid, Research Institute 12 de Octubre University Hospital (i+12), CIBERONC, Madrid, Spain
| | - M C Copin
- Department of Pathology, Université d'Angers, Centre Hospitalier Universitaire d'Angers, Angers, France
| | - J F Côté
- Department of Pathology, Institut Mutualiste Montsouris, Paris, France
| | - N D'Haene
- Department of Pathology, Erasme Hospital, HUB ULB, Brussels, Belgium
| | - H Y Dai
- Department of Pathology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway
| | - L de Leval
- Institute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - P Delongova
- Institute of Molecular and Clinical Pathology and Medical Genetics, Faculty of Medicine, University Hospital Ostrava, Ostrava, Czech Republic
| | | | - A Fabre
- Department of Histopathology, St. Vincent's University Hospital, University College Dublin School of Medicine, Dublin, Ireland
| | - F Ferenc
- Department of Pathology, University of Oradea, Oradea, Romania
| | - F Forest
- Department of Pathology, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - F de Fraipont
- Medical Unit of Molecular Genetic (Hereditary Diseases and Oncology), Grenoble University Hospital, Grenoble, France
| | - M Garcia-Martos
- Department of Pathology, Gregorio Marañón General University Hospital, Madrid, Spain
| | - G Gauchotte
- Department of Biopathology, CHRU-ICL, CHRU Nancy, Vandoeuvre-lès-Nancy, France
| | - R Geraghty
- Department of Histopathology, St. Vincent's University Hospital, University College Dublin School of Medicine, Dublin, Ireland
| | - E Guerin
- Department of Molecular Cancer Genetics, Laboratory of Biochemistry and Molecular Biology, University Hospital of Strasbourg, Strasbourg, France
| | - D Guerrero
- Biomedical Research Centre, Navarra Health Service, Pamplona, Navarra, Spain
| | - S Hernandez
- Department of Pathology, 12 de Octubre University Hospital, Universidad Complutense de Madrid, Research Institute 12 de Octubre University Hospital (i+12), CIBERONC, Madrid, Spain
| | - P Hurník
- Institute of Molecular and Clinical Pathology and Medical Genetics, Faculty of Medicine, University Hospital Ostrava, Ostrava, Czech Republic
| | - B Jean-Jacques
- Department of Pathology, CHU de Caen Côte de Nacre, Caen, France
| | - K Kashofer
- Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria
| | - D Kazdal
- Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), member of the German Center for Lung Research (DZL), Heidelberg, Germany
| | - S Lantuejoul
- Department of Biopathology, Centre Leon Berard Unicancer and Pathology Research Platform, Cancer Research Center of Lyon (CRCL), Lyon, France
| | - C Leonce
- Department of Pathology, Groupement Hospitalier Est, Bron, France
| | - A Lupo
- Department of Pathology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université de Paris, Paris, France
| | - U Malapelle
- Department of Public Health, University of Naples Federico II, Naples, Italy
| | - R Matej
- Department of Pathology and Molecular Medicine, Thomayer University Hospital, Prague, Czech Republic
| | - J L Merlin
- Department of Biopathology, Institut de Cancérologie de Lorraine, University of Lorraine, Vandoeuvre-Les-Nancy, France
| | - K D Mertz
- Institute of Pathology, Cantonal Hospital Baselland, Liestal, Switzerland
| | - A Morel
- Department of Innate Immunity and Immunotherapy, Institut de Cancérologie de l'Ouest - Centre Paul Papin, Angers, France
| | - A Mutka
- HUSLAB, Department of Pathology, Helsinki University Hospital, Helsinki, Finland
| | - N Normanno
- Cell Biology and Biotherapy Unit, INT-Fondazione Pascale, Via M. Semmola, Naples, Italy
| | - P Ovidiu
- Department of Pathology, University of Oradea, Oradea, Romania
| | - A Panizo
- Department of Pathology, Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain
| | - M G Papotti
- Division of Pathology, University Hospital Città Della Salute, Turin, Italy
| | - E Parobkova
- Department of Pathology and Molecular Medicine, Thomayer University Hospital, Prague, Czech Republic
| | - G Pasello
- Division of Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy
| | - P Pauwels
- Department of Pathology, University Hospital Antwerp and University of Antwerp, Antwerp, Belgium
| | - G Pelosi
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
| | - F Penault-Llorca
- Department of Pathology, Clermont Auvergne University, "Molecular Imaging and Theranostic Strategies", Center Jean Perrin, Montalembert, Clermont-Ferrand, France
| | - T Picot
- Department of Pathology, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - N Piton
- Department of Pathology, Rouen University Hospital, France and Normandie University, UNIROUEN, Inserm U1245, Rouen, France
| | - A Pittaro
- Division of Pathology, University Hospital Città Della Salute, Turin, Italy
| | - G Planchard
- Department of Pathology, CHU de Caen Côte de Nacre, Caen, France
| | - N Poté
- Department of Pathology, Hospital Bichat Bichat, Assistance Publique Hôpitaux de Paris; Université Paris Cité, Paris, France
| | - T Radonic
- Department of Pathology, Amsterdam University Medical Center, VUMC, University of Amsterdam, Amsterdam, Netherlands
| | - I Rapa
- Pathology Unit, San Luigi Hospital, Orbassano Turin, Italy
| | - A Rappa
- Oncogenomics Unit, European Institute of Oncology (IEO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy
| | - C Roma
- Cell Biology and Biotherapy Unit, INT-Fondazione Pascale, Via M. Semmola, Naples, Italy
| | - M Rot
- Department of Pathology, University Clinic Golnik, Golnik, Slovenia
| | - J C Sabourin
- Department of Pathology, Rouen University Hospital, France and Normandie University, UNIROUEN, Inserm U1245, Rouen, France
| | - I Salmon
- Department of Pathology, Erasme Hospital, HUB ULB, Brussels, Belgium; CurePath, Jumet, Belgium
| | - S Savic Prince
- Department of Pathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland
| | - A Scarpa
- Department of Diagnostics and Public Health, Section of Pathology, University and Hospital Trust of Verona, Verona, Italy
| | - E Schuuring
- Department of Pathology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
| | - I Serre
- Department of Pathology, Gui de Chauliac Hospital, Montpellier University Medical Center, University of Montpellier, 80 Avenue Augustin Fliche, Montpellier, France
| | - V Siozopoulou
- Department of Pathology, University Hospital Antwerp and University of Antwerp, Antwerp, Belgium
| | - D Sizaret
- Department of Pathology, CHRU Tours - Hôpital Trousseau, Chambray-lès-Tours, France
| | - S Smojver-Ježek
- Division for Pulmonary Cytology, Department of Pathology and Cytology, University Hospital Centre Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - J Solassol
- Solid Tumour Laboratory, Pathology and Oncobiology Department, CHU Montpellier, University of Montpellier, Montpellier, France
| | - K Steinestel
- Institute of Pathology and Molecular Pathology, Bundeswehrkrankenhaus Ulm, Oberer Eselsberg 40, 89081 Ulm, Germany
| | - J Stojšić
- Department of Thoracic Pathology, Section of Pathology, University Clinical Centre of Serbia, Belgrade, Serbia
| | - C Syrykh
- Department of Pathology, IUC-T-Oncopole, Toulouse, France
| | - S Timofeev
- Multidisciplinary Clinical Center "Kommunarka" of the Moscow Health Department, Moscow, Russia
| | - G Troncone
- Department of Pathology, University of Oradea, Oradea, Romania
| | - A Uguen
- Department of Pathological Anatomy and Cytology, CHRU de Brest, Brest, France; LBAI, UMR1227, INSERM, University of Brest, CHU de Brest, Brest, France
| | - S Valmary-Degano
- Department of Pathology, Institute for Advanced Biosciences, CHU Grenoble Alpes, Université Grenoble Alpes, Grenoble, France
| | - A Vigier
- Department of Pathology, IUC-T-Oncopole, Toulouse, France
| | - M Volante
- Department of Oncology, University of Turin, San Luigi Hospital, Orbassano, Turin, Italy
| | - S G F Wahl
- Department of Pathology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway
| | - A Stenzinger
- Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), member of the German Center for Lung Research (DZL), Heidelberg, Germany
| | - M Ilié
- Laboratory of Clinical and Experimental Pathology, FHU OncoAge, Biobank Côte d'Azur BB-0033-00025, Louis Pasteur Hospital, IRCAN, Université Côte d'Azur, Nice, France
| |
Collapse
|
2
|
Hofman P, Ilié M, Chamorey E, Brest P, Schiappa R, Nakache V, Antoine M, Barberis M, Begueret H, Bibeau F, Bonnetaud C, Boström P, Brousset P, Bubendorf L, Carvalho L, Cathomas G, Cazes A, Chalabreysse L, Chenard MP, Copin MC, Côté JF, Damotte D, de Leval L, Delongova P, Thomas de Montpreville V, de Muret A, Dema A, Dietmaier W, Evert M, Fabre A, Forest F, Foulet A, Garcia S, Garcia-Martos M, Gibault L, Gorkiewicz G, Jonigk D, Gosney J, Hofman A, Kern I, Kerr K, Kossai M, Kriegsmann M, Lassalle S, Long-Mira E, Lupo A, Mamilos A, Matěj R, Meilleroux J, Ortiz-Villalón C, Panico L, Panizo A, Papotti M, Pauwels P, Pelosi G, Penault-Llorca F, Pop O, Poté N, Cajal SRY, Sabourin JC, Salmon I, Sajin M, Savic-Prince S, Schildhaus HU, Schirmacher P, Serre I, Shaw E, Sizaret D, Stenzinger A, Stojsic J, Thunnissen E, Timens W, Troncone G, Werlein C, Wolff H, Berthet JP, Benzaquen J, Marquette CH, Hofman V, Calabrese F. Clinical and molecular practice of European thoracic pathology laboratories during the COVID-19 pandemic. The past and the near future. ESMO Open 2020; 6:100024. [PMID: 33399086 PMCID: PMC7780004 DOI: 10.1016/j.esmoop.2020.100024] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2020] [Revised: 11/19/2020] [Accepted: 11/21/2020] [Indexed: 12/18/2022] Open
Abstract
Background This study evaluated the consequences in Europe of the COVID-19 outbreak on pathology laboratories orientated toward the diagnosis of thoracic diseases. Materials and methods A survey was sent to 71 pathology laboratories from 21 European countries. The questionnaire requested information concerning the organization of biosafety, the clinical and molecular pathology, the biobanking, the workload, the associated research into COVID-19, and the organization of education and training during the COVID-19 crisis, from 15 March to 31 May 2020, compared with the same period in 2019. Results Questionnaires were returned from 53/71 (75%) laboratories from 18 European countries. The biosafety procedures were heterogeneous. The workload in clinical and molecular pathology decreased dramatically by 31% (range, 3%-55%) and 26% (range, 7%-62%), respectively. According to the professional category, between 28% and 41% of the staff members were not present in the laboratories but did teleworking. A total of 70% of the laboratories developed virtual meetings for the training of residents and junior pathologists. During the period of study, none of the staff members with confirmed COVID-19 became infected as a result of handling samples. Conclusions The COVID-19 pandemic has had a strong impact on most of the European pathology laboratories included in this study. Urgent implementation of several changes to the organization of most of these laboratories, notably to better harmonize biosafety procedures, was noted at the onset of the pandemic and maintained in the event of a new wave of infection occurring in Europe. Biosafety measures used in the first wave of the COVID-19 crisis were heterogeneous in 53 European pathology laboratories. A dramatic decrease of the workload in pathology laboratories was noted. No case of healthcare workers contaminated with SARS-CoV-2 associated with samples handling was identified.
Collapse
Affiliation(s)
- P Hofman
- Laboratory of Clinical and Experimental Pathology, FHU OncoAge, BB-0033-00025, Louis Pasteur Hospital, IRCAN, Université Côte d'Azur, Nice, France.
| | - M Ilié
- Laboratory of Clinical and Experimental Pathology, FHU OncoAge, BB-0033-00025, Louis Pasteur Hospital, IRCAN, Université Côte d'Azur, Nice, France
| | - E Chamorey
- Epidemiology and Biostatistics Unit, Centre Antoine-Lacassagne, Université Côte d'Azur, Nice, France
| | - P Brest
- Team 4, IRCAN, INSERM, CNRS, Centre Antoine-Lacassagne, Université Côte d'Azur, Nice, France
| | - R Schiappa
- Epidemiology and Biostatistics Unit, Centre Antoine-Lacassagne, Université Côte d'Azur, Nice, France
| | - V Nakache
- Laboratory of Clinical and Experimental Pathology, FHU OncoAge, BB-0033-00025, Louis Pasteur Hospital, IRCAN, Université Côte d'Azur, Nice, France
| | - M Antoine
- Department of Pathology, Hôpital Tenon, AP-HP, Paris, France
| | - M Barberis
- Unit of Histopathology and Molecular Diagnostics, Division of Pathology, IEO, European Institute of Oncology, IRCCS, Milan, Italy
| | - H Begueret
- Department of Pathology, University Hospital of Bordeaux, Bordeaux, France
| | - F Bibeau
- Department of Pathology, CHU de Caen, Université de Caen Normandie, Caen, France
| | - C Bonnetaud
- Laboratory of Clinical and Experimental Pathology, FHU OncoAge, BB-0033-00025, Louis Pasteur Hospital, IRCAN, Université Côte d'Azur, Nice, France
| | - P Boström
- Department of Pathology, Turku University Hospital, Turku, Finland
| | - P Brousset
- Department of Pathology, IUC-T-Oncopole, Inserm U1037 CRCT, Université de Toulouse, Toulouse, France
| | - L Bubendorf
- Institute of Pathology, Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland
| | - L Carvalho
- Institute of Anatomical and Molecular Pathology and University Hospital, University of Coimbra, Coimbra, Portugal
| | - G Cathomas
- Institute of Pathology, Cantonal Hospital Baselland, Liestal, Switzerland
| | - A Cazes
- Department of Pathology, Bichat Hospital, AP-HP, Inserm UMR 1152, Université de Paris, Paris, France
| | - L Chalabreysse
- Department of Pathology, Groupement Hospitalier Est, Hospices Civils de Lyon, Lyon, France
| | - M-P Chenard
- Department of Pathology, University Hospital of Strasbourg, Strasbourg, France
| | - M-C Copin
- Institut de Pathologie, CHU Lille, Université de Lille, Lille, France
| | - J-F Côté
- Department of Pathology, Institut Mutualiste Montsouris, Paris, France
| | - D Damotte
- Department of Pathology, Hôpitaux Universitaires Paris Centre, Hôpital Cochin, Inserm U1138, Université de Paris, Paris, France
| | - L de Leval
- Institute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and Lausanne University, Lausanne, Switzerland
| | - P Delongova
- Institute of Pathology, University Hospital Ostrava, Ostrava, Czech Republic
| | | | - A de Muret
- Department of Pathology, University Hospital of Tours, Tours, France
| | - A Dema
- Department of Pathology, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania
| | - W Dietmaier
- Institute of Pathology, University of Regensburg, Regensburg, Germany
| | - M Evert
- Institute of Pathology, University of Regensburg, Regensburg, Germany
| | - A Fabre
- Department of Histopathology, St Vincent's University Hospital, University College Dublin School of Medicine, Dublin, Ireland
| | - F Forest
- Department of Pathology, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - A Foulet
- Department of Pathology, Centre Hospitalier, Le Mans, France
| | - S Garcia
- Department of Pathology, Hôpital Nord, AP-HM, Aix Marseille University, Marseille, France
| | - M Garcia-Martos
- Pulmonary Pathology Department, Gregorio Marañon University Hospital, Madrid, Spain
| | - L Gibault
- Department of Pathology, Hôpital Européen Georges Pompidou, AP-HP, Université de Paris, Paris, France
| | - G Gorkiewicz
- Institute of Pathology, Medical University of Graz, Graz, Austria
| | - D Jonigk
- Institute of Pathology, German Center for Lung Research, Biomedical Research in Endstage and Obstructive Lung Disease Hannover, Hannover Medical School, Hannover, Germany
| | - J Gosney
- Liverpool University Hospitals, Royal Liverpool University Hospital, Liverpool, UK
| | - A Hofman
- Laboratory of Clinical and Experimental Pathology, FHU OncoAge, BB-0033-00025, Louis Pasteur Hospital, IRCAN, Université Côte d'Azur, Nice, France
| | - I Kern
- Department of Pathology, University Clinic Golnik, Golnik, Slovenia
| | - K Kerr
- Department of Pathology, Aberdeen Royal Infirmary, Aberdeen, UK
| | - M Kossai
- Department of Pathology and Molecular Pathology, Centre Jean Perrin, Clermont-Ferrand, France
| | - M Kriegsmann
- Institute of Pathology, University Hospital Heidelberg, Heidelberg, and German Center for Lung Research (DZL), Germany
| | - S Lassalle
- Laboratory of Clinical and Experimental Pathology, FHU OncoAge, BB-0033-00025, Louis Pasteur Hospital, IRCAN, Université Côte d'Azur, Nice, France
| | - E Long-Mira
- Laboratory of Clinical and Experimental Pathology, FHU OncoAge, BB-0033-00025, Louis Pasteur Hospital, IRCAN, Université Côte d'Azur, Nice, France
| | - A Lupo
- Department of Pathology, Hôpitaux Universitaires Paris Centre, Hôpital Cochin, Inserm U1138, Université de Paris, Paris, France
| | - A Mamilos
- Institute of Pathology, University of Regensburg, Regensburg, Germany
| | - R Matěj
- Department of Pathology and Molecular Medicine, Third Faculty of Medicine, Charles University, Thomayer Hospital and University Hospital Kralovske Vinohrady, Prague, Czech Republic
| | - J Meilleroux
- Department of Pathology, IUC-T-Oncopole, Inserm U1037 CRCT, Université de Toulouse, Toulouse, France
| | - C Ortiz-Villalón
- Department of Pathology, Karolinska University Hospital, Stockholm, Sweden
| | - L Panico
- Unit of Pathology, Azienda Ospedaliera dei Colli, Monaldi-Cotugno-CTO, Naples, Italy
| | - A Panizo
- Department of Pathology, Complejo Hospitalario de Navarra, Pamplona, Spain
| | - M Papotti
- Department of Oncology, University of Torino, Torino, Italy
| | - P Pauwels
- Centre for Oncological Research (CORE), University of Antwerp, Antwerp, Belgium
| | - G Pelosi
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, and IRCCS MultiMedica, Milan, Italy
| | - F Penault-Llorca
- Department of Pathology and Molecular Pathology, Centre Jean Perrin, Clermont-Ferrand, France
| | - O Pop
- Department of Pathology, University of Oradea, Oradea, Romania
| | - N Poté
- Department of Pathology, Bichat Hospital, AP-HP, Inserm UMR 1152, Université de Paris, Paris, France
| | - S R Y Cajal
- Department of Pathology, Vall d'Hebron University Hospital, Barcelona, Spain
| | - J-C Sabourin
- Department of Pathology, Inserm 1245, Rouen University Hospital Normandy University, Rouen, France
| | - I Salmon
- Department of Pathology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
| | - M Sajin
- Department of Pathology, Emergency University Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
| | - S Savic-Prince
- Institute of Pathology, Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland
| | - H-U Schildhaus
- Institute of Pathology, University Hospital Essen, Essen, Germany
| | - P Schirmacher
- Institute of Pathology, University Hospital Heidelberg, Heidelberg, and German Center for Lung Research (DZL), Germany
| | - I Serre
- Department of Biopathology, Gui de Chauliac Hospital, Montpellier University Hospital, Montpellier, France
| | - E Shaw
- Department of Cellular Pathology, University Hospital Southampton NHS Foundation Trust, Southampton, UK
| | - D Sizaret
- Department of Pathology, University Hospital of Tours, Tours, France
| | - A Stenzinger
- Institute of Pathology, University Hospital Heidelberg, Heidelberg, and German Center for Lung Research (DZL), Germany
| | - J Stojsic
- Department of Thoracic Pathology, Service of Pathology, University Clinical Centre of Serbia, Belgrade, Serbia
| | - E Thunnissen
- Department of Pathology, Amsterdam University Medical Centres, Location VUmc, Amsterdam, The Netherlands
| | - W Timens
- Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - G Troncone
- Department of Public Health, University of Naples Frederico II, Naples, Italy
| | - C Werlein
- Institute of Pathology, German Center for Lung Research, Biomedical Research in Endstage and Obstructive Lung Disease Hannover, Hannover Medical School, Hannover, Germany
| | - H Wolff
- Laboratory of Pathology, Finnish Institute of Occupational Health, Helsinki, Finland
| | - J-P Berthet
- Department of Thoracic Surgery, FHU OnoAge, Louis Pasteur Hospital, University Côte d'Azur, Nice, France
| | - J Benzaquen
- Department of Pneumology, FHU OncoAge, Louis Pasteur Hospital, IRCAN, Université Côte d'Azur, Nice, France
| | - C-H Marquette
- Department of Pneumology, FHU OncoAge, Louis Pasteur Hospital, IRCAN, Université Côte d'Azur, Nice, France
| | - V Hofman
- Laboratory of Clinical and Experimental Pathology, FHU OncoAge, BB-0033-00025, Louis Pasteur Hospital, IRCAN, Université Côte d'Azur, Nice, France
| | - F Calabrese
- Department of Cardiac, Thoracic, Vascular Sciences and Public Health, Pathological Anatomy Section, University of Padova Medical School, Padova, Italy
| |
Collapse
|
3
|
Özdemir BC, Latifyan S, Perreau M, Fenwick C, Alberio L, Waeber G, Spertini F, de Leval L, Michielin O, Obeid M. Cytokine-directed therapy with tocilizumab for immune checkpoint inhibitor-related hemophagocytic lymphohistiocytosis. Ann Oncol 2020; 31:1775-1778. [PMID: 32858151 DOI: 10.1016/j.annonc.2020.08.2101] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2020] [Revised: 08/03/2020] [Accepted: 08/12/2020] [Indexed: 12/20/2022] Open
Affiliation(s)
- B C Özdemir
- Centre Hospitalier Universitaire Vaudois (CHUV), Service of Medical Oncology Department of Oncology, Lausanne, Switzerland; International Cancer Prevention Institute, Epalinges, Switzerland
| | - S Latifyan
- Centre Hospitalier Universitaire Vaudois (CHUV), Service of Medical Oncology Department of Oncology, Lausanne, Switzerland
| | - M Perreau
- Centre Hospitalier Universitaire Vaudois (CHUV), Service of Immunology and Allergy, Department of Medicine, Lausanne, Switzerland; University Hospital of Lausanne, Lausanne, Switzerland
| | - C Fenwick
- Centre Hospitalier Universitaire Vaudois (CHUV), Service of Immunology and Allergy, Department of Medicine, Lausanne, Switzerland
| | - L Alberio
- University Hospital of Lausanne, Lausanne, Switzerland; Centre Hospitalier Universitaire Vaudois (CHUV), Service of Hematology Division, Department of Oncology and Central Hematology Laboratory, Department of Laboratory Medicine and Pathology, Lausanne, Switzerland
| | - G Waeber
- Centre Hospitalier Universitaire Vaudois (CHUV), Service of Immunology and Allergy, Department of Medicine, Lausanne, Switzerland; University Hospital of Lausanne, Lausanne, Switzerland
| | - F Spertini
- Centre Hospitalier Universitaire Vaudois (CHUV), Service of Immunology and Allergy, Department of Medicine, Lausanne, Switzerland; University Hospital of Lausanne, Lausanne, Switzerland
| | - L de Leval
- University Hospital of Lausanne, Lausanne, Switzerland; Centre Hospitalier Universitaire Vaudois (CHUV), Institute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne, Switzerland
| | - O Michielin
- Centre Hospitalier Universitaire Vaudois (CHUV), Service of Medical Oncology Department of Oncology, Lausanne, Switzerland; University Hospital of Lausanne, Lausanne, Switzerland
| | - M Obeid
- Centre Hospitalier Universitaire Vaudois (CHUV), Service of Immunology and Allergy, Department of Medicine, Lausanne, Switzerland; University Hospital of Lausanne, Lausanne, Switzerland; Centre Hospitalier Universitaire Vaudois (CHUV), Vaccine and Immunotherapy Center, Lausanne, Switzerland.
| |
Collapse
|
4
|
Lemonnier F, Safar V, Ferchiou A, Cottereau A, Bachy E, Cartron G, Moles-Moreau M, Delmer A, Bouabdallah R, Voillat L, Parrens M, Casasnovas O, Cacheux V, Réguy C, Tilly H, Meignan M, Gaulard P, de Leval L, Delfau-Larrue M, Haioun C. BONE MARROW INVOLVEMENT, BUT NO BLOOD INVOLVEMENT, IMPAIRS SURVIVAL IN ANGIOIMMUNOBLASTIC T CELL LYMPHOMA: AN ANCILLARY STUDY OF THE REVAIL TRIAL. Hematol Oncol 2019. [DOI: 10.1002/hon.89_2630] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- F. Lemonnier
- Unité Hémopathies Lymphoïdes, INSERMU955; Université Paris Est, Hôpitaux Universitaires Henri Mondor; Créteil France
| | - V. Safar
- Hématologie; Hôpital Lyon Sud; Pierre Bénite France
| | - A. Ferchiou
- Laboratoire d'immunologie; Université Paris Est, Hôpitaux Universitaires Henri Mondor; Créteil France
| | - A. Cottereau
- Département de Médecine Nucléaire; Hopital Cochin; Paris France
| | - E. Bachy
- Hématologie; Hôpital Lyon Sud; Pierre Bénite France
| | - G. Cartron
- Département d'Hématologie Clinique; CHU Montpellier; Montpellier France
| | | | - A. Delmer
- Service d'Hématologie Clinique; CHU Reims; Reims France
| | - R. Bouabdallah
- Service d'Hématologie; Institut Paoli Calmette; Marseille France
| | - L. Voillat
- Service d'Hématologie; CH Chalon sur Saône; Chalon-sur-Saône France
| | - M. Parrens
- Service de Pathologie; CHU Bordeaux Haut Levèque; Pessac France
| | | | - V. Cacheux
- Service d'Hématologie; CHU de Clermont-Ferrand; Clermont Ferrand France
| | - C. Réguy
- Service d'Hématologie; CHU Grenoble; La Tronche France
| | - H. Tilly
- Service d'Hématologie; Centre Henri Becquerel; Rouen France
| | | | - P. Gaulard
- Département de Pathologie; Hôpital Henri Mondor; Créteil France
| | - L. de Leval
- Département de Pathologie; Centre Hospitalier Universitaire Vaudois; Lausanne Switzerland
| | - M. Delfau-Larrue
- Laboratoire d'immunologie; Université Paris Est, Hôpitaux Universitaires Henri Mondor; Créteil France
| | - C. Haioun
- Unité Hémopathies Lymphoïdes, INSERMU955; Université Paris Est, Hôpitaux Universitaires Henri Mondor; Créteil France
| |
Collapse
|
5
|
de Leval L. NEW DATA IN THE MOLECULAR PATHOLOGY OF T-CELL LYMPHOMAS. Hematol Oncol 2019. [DOI: 10.1002/hon.120_2629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- L. de Leval
- Institute of Pathology; Lausanne University Hospital; Lausanne Switzerland
| |
Collapse
|
6
|
Bruscaggin A, Mollejo M, Tapia G, Gomes da Silva M, Novak U, Dietrich S, Ponzoni M, Rambaldi A, Corradini P, Vitolo U, Merli M, Tzankov A, Cogliatti S, Montalban C, Marasca R, de Leval L, Visco C, Baptista M, Tousseyn T, Facchetti F, Paulli M, Mazzucchelli L, Bea S, Oscier D, Zinzani P, Bhagat G, Inghirami G, Gaidano G, Traverse-Glehen A, Thieblemont C, Piris M, Cavalli F, Arcaini L, Zucca E, Rossi D. MULTI-OMICS LANDSCAPE OF SPLENIC MARGINAL ZONE LYMPHOMA (SMZL) - INTERIM ANALYSIS OF IELSG46 STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.138_2629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
7
|
Broutin S, Dupuy A, Koscielny S, Fataccioli V, Lemonnier F, de Leval L, Robe C, Pujals A, Safar V, Delarue R, Delfau-Larue M, Ribrag V, Haioun C, Gaulard P, Paci A. SERUM 2-HYDROXYGLUTARATE, A PREDICTIVE BIOMARKER OF THE PRESENCE OF IDH2
MUTATIONS IN AITL PATIENTS. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- S. Broutin
- Service de Pharmacologie, Département de Biologie et Pathologie Médicales; Gustave Roussy & Université Paris-Saclay; Villejuif France
| | - A. Dupuy
- INSERM U955, Institut Mondor de Recherche Biomédicale; Université Paris-Est; Créteil France
| | - S. Koscielny
- Service de Biostatistique et d'Epidemiologie & INSERM U1018; Gustave Roussy & Université Paris-Saclay; Villejuif France
| | - V. Fataccioli
- INSERM U955, Institut Mondor de Recherche Biomédicale; Université Paris-Est; Créteil France
| | - F. Lemonnier
- Unité Hémopathies lymphoides & INSERM U955; Hôpitaux Universitaires Henri Mondor & Université Paris-Est; Créteil France
| | - L. de Leval
- Département de Pathologie & INSERM U955; Centre Hospitalier Universitaire Vaudois & Institute Mondor de Recherche Biomédicale, Université Paris-Est, Lausanne; Suisse & Créteil France
| | - C. Robe
- INSERM U955, Institut Mondor de Recherche Biomédicale; Université Paris-Est; Créteil France
| | - A. Pujals
- Département de Pathologie & INSERM U955; Hôpitaux Universitaires Henri Mondor & Université Paris-Est; Créteil France
| | - V. Safar
- Service d'Hématologie Clinique, Hospices Civils de Lyon; Pierre-Bénite France
| | - R. Delarue
- Clinical Hematology & INSERM UMR1163 & CNRS ERL 8254; Necker Hospital & IMAGINE Institute; Paris France
| | - M.H. Delfau-Larue
- Service d'Immulogie Biologique & INSERM U955; Hôpitaux Universitaires Henri Mondor & Université Paris-Est; Créteil France
| | - V. Ribrag
- Service d'Hématologie; Gustave Roussy & Université Paris-Saclay; Villejuif France
| | - C. Haioun
- Unité Hémopathies lymphoides & INSERM U955; Hôpitaux Universitaires Henri Mondor & Université Paris-Est; Créteil France
| | - P. Gaulard
- Département de Pathologie & INSERM U955; Hôpitaux Universitaires Henri Mondor & Université Paris-Est; Créteil France
| | - A. Paci
- Service de Pharmacologie, Département de Biologie et Pathologie Médicales; Gustave Roussy & Université Paris-Saclay; Villejuif France
| |
Collapse
|
8
|
Vallois D, Dupuy A, Lemonnier F, Fataccioli V, Ortonne N, Allen G, Tournilhac O, Delarue R, Rousselet-Chapeau M, Fabiani B, Llamas-Gutierrez F, Ko Y, Kataoka K, Gaulard P, de Leval L. TANSLOCATIONS INVOLVING CD28
ARE RARE IN PERIPHERAL T-CELL LYMPHOMAS. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_22] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- D. Vallois
- Institute of Pathology; Centre Hospitalier Universitaire Vaudois; Lausanne Switzerland
| | - A. Dupuy
- Département de Pathologie, INSERM U955, Hôpital Henri-Mondor; Créteil France
| | - F. Lemonnier
- Département de Pathologie, INSERM U955, Hôpital Henri-Mondor; Créteil France
| | - V. Fataccioli
- Département de Pathologie, INSERM U955, Hôpital Henri-Mondor; Créteil France
| | - N. Ortonne
- Département de Pathologie, INSERM U955, Hôpital Henri-Mondor; Créteil France
| | - G. Allen
- Institute of Pathology; Centre Hospitalier Universitaire Vaudois; Lausanne Switzerland
| | - O. Tournilhac
- Hématologie Clinique; CHU Estaing; Clermont-Ferrand France
| | - R. Delarue
- Hématologie Clinique; HU-Necker enfants malades; Paris France
| | | | - B. Fabiani
- Anatomie et Cytologie Pathologiques; Hôpital Saint-Antoine; Paris France
| | | | - Y.H. Ko
- Department of Pathology; Samsung Medical Center; Seoul South Korea
| | - K. Kataoka
- Department of Pathology and Tumor Biology; Kyoto University; Kyoto Japan
| | - P. Gaulard
- Département de Pathologie, INSERM U955, Hôpital Henri-Mondor; Créteil France
| | - L. de Leval
- Institute of Pathology; Centre Hospitalier Universitaire Vaudois; Lausanne Switzerland
| |
Collapse
|
9
|
Lemonnier F, Safar V, Cottereau A, Fataccioli V, Chaillol I, Pelletier R, Letourneau A, Dupuy A, Bossard C, Martin A, Robe C, Pelletier L, Pujals A, Bachy E, Delmer A, Moles Moreau M, Tilly H, Parrens M, Delfau-Larue M, Missiaglia E, Meignan M, de Leval L, Haioun C, Gaulard P. INTEGRATIVE ANALYSIS OF FEATURES ASSOCIATED WITH TET2, IDH2, DNMT3A, AND RHOA MUTATIONS IN ANGIOIMMUNOBLASTIC T CELL LYMPHOMA: A LYSA STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- F. Lemonnier
- INSERMU955, Unité Hémopathies Lymphoïdes; Université Paris Est, Hôpitaux universitaire Henri Mondor; Créteil France
| | - V. Safar
- Hématologie clinique; Centre Hopsitalier Lyon Sud; Pierre Bénite France
| | - A. Cottereau
- Médecine nucléaire; Hôpital Tenon, APHP; Paris France
| | - V. Fataccioli
- INSERMU955; Institut Mondor de Recherche Biomédicale; Créteil France
| | - I. Chaillol
- Lysarc; Centre Hospitalier Lyon Sud; Pierre Bénite France
| | - R. Pelletier
- INSERMU955; Institut Mondor de Recherche Biomédicale; Créteil France
| | - A. Letourneau
- Pathologie; Centre Hospitalier Universitaire Vaudois; Lausanne Switzerland
| | - A. Dupuy
- INSERMU955; Institut Mondor de Recherche Biomédicale; Créteil France
| | - C. Bossard
- Anatomie et cytologie pathologique; Hotel Dieu, CHU Nantes; Nantes France
| | - A. Martin
- anatomie pathologique, Hôpital Avicenne; Bobigny France
| | - C. Robe
- INSERMU955; Institut Mondor de Recherche Biomédicale; Créteil France
| | - L. Pelletier
- INSERMU955; Institut Mondor de Recherche Biomédicale; Créteil France
| | - A. Pujals
- INSERMU955, Département de Pathologie; Université Paris Est, Hôpitaux Universitaires Henri Mondor; Créteil France
| | - E. Bachy
- Lysarc; Centre Hospitalier Lyon Sud; Pierre Bénite France
| | - A. Delmer
- hématologie clinique; centre hospitalier universitaire; Reims France
| | - M. Moles Moreau
- hématologie clinique; centre hospitalier universitaire; Angers France
| | - H. Tilly
- Hématologie clinique; CLCC Henri Becquerel; Rouen France
| | - M. Parrens
- Pathologie; Hôpital Haut-Lévêque; Pessac France
| | - M. Delfau-Larue
- Immunologie biologique; Hôpitaux universitaires Henri Mondor; Créteil France
| | - E. Missiaglia
- Pathologie; Centre Hospitalier Universitaire Vaudois; Lausanne Switzerland
| | - M. Meignan
- LYSA image; Hôpitaux Universitaires Henri Mondor; Créteil France
| | - L. de Leval
- Pathologie; Centre Hospitalier Universitaire Vaudois; Lausanne Switzerland
| | - C. Haioun
- INSERMU955, Unité Hémopathies Lymphoïdes; Université Paris Est, Hôpitaux universitaire Henri Mondor; Créteil France
| | - P. Gaulard
- INSERMU955, Département de Pathologie; Université Paris Est, Hôpitaux Universitaires Henri Mondor; Créteil France
| |
Collapse
|
10
|
Hajdu SD, de Leval L, Meuwly JY. Title Page - Contrast-Enhanced Ultrasound of Nodular Splenic Extramedullary Hematopoiesis in a Patient with Underlying Primary Myelofibrosis. Ultraschall Med 2016; 37:447-450. [PMID: 26331329 DOI: 10.1055/s-0035-1553590] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
|
11
|
Cottereau A, Becker S, Broussais F, Casasnovas O, Kanoun S, Roques M, Charrier N, Bertrand S, Delarue R, Bonnet C, Hustinx R, Gaulard P, de Leval L, Vera P, Itti E, Mounier N, Haioun C, Tilly H, Meignan M. Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL). Ann Oncol 2016; 27:719-24. [DOI: 10.1093/annonc/mdw011] [Citation(s) in RCA: 72] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2015] [Accepted: 12/24/2015] [Indexed: 12/13/2022] Open
|
12
|
Affiliation(s)
- J. Quartiers
- Department of Cardiovascular Surgery, University of Liège Hospital, Liège Belgium
| | - R. Durieux
- Department of Cardiovascular Surgery, University of Liège Hospital, Liège Belgium
| | - L. de Leval
- Department of Anatomopathology, University of Liège Hospital, Liège Belgium
| | - R. Limet
- Department of Cardiovascular Surgery, University of Liège Hospital, Liège Belgium
| |
Collapse
|
13
|
Laurent C, Delas A, Gaulard P, Haioun C, Moreau A, Xerri L, Traverse-Glehen A, Rousset T, Quintin-Roue I, Petrella T, Emile JF, Amara N, Rochaix P, Chenard-Neu MP, Tasei AM, Menet E, Chomarat H, Costes V, Andrac-Meyer L, Michiels JF, Chassagne-Clement C, de Leval L, Brousset P, Delsol G, Lamant L. Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes. Ann Oncol 2015; 27:306-14. [PMID: 26598546 DOI: 10.1093/annonc/mdv575] [Citation(s) in RCA: 155] [Impact Index Per Article: 17.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2015] [Accepted: 11/11/2015] [Indexed: 02/01/2023] Open
Abstract
BACKGROUND ALK-negative anaplastic large cell lymphoma associated with breast implant (i-ALCL) has been recently recognized as a distinct entity. Among 43 830 lymphomas registered in the French Lymphopath network since 2010, 300 breast lymphomas comprising 25 peripheral T-cell lymphomas (PTCL) were reviewed. Among PTCL, ALK-negative ALCL was the most frequent and all of them were associated with breast implants. PATIENTS AND METHODS Since 2010, all i-ALCL cases were collected from different institutions through Lymphopath. Immuno-morphologic features, molecular data and clinical outcome of 19 i-ALCLs have been retrospectively analyzed. RESULTS The median age of the patients was 61 years and the median length between breast implant and i-ALCL was 9 years. Most implants were silicone-filled and textured. Implant removal was performed in 17 out of 19 patients with additional treatment based on mostly CHOP or CHOP-like chemotherapy regimens (n = 10/19) or irradiation (n = 1/19). CHOP alone or ABVD following radiation without implant removal have been given in two patients. The two clinical presentations, i.e. effusion and less frequently tumor mass correlated with distinct histopathologic features: in situ i-ALCL (anaplastic cell proliferation confined to the fibrous capsule) and infiltrative i-ALCL (pleomorphic cells massively infiltrating adjacent tissue with eosinophils and sometimes Reed-Sternberg-like cells mimicking Hodgkin lymphoma). Malignant cells were CD30-positive, showed a variable staining for EMA and were ALK negative. Most cases had a cytotoxic T-cell immunophenotype with variable T-cell antigen loss and pSTAT3 nuclear expression. T-cell receptor genes were clonally rearranged in 13 out of 13 tested cases. After 18 months of median follow-up, the 2-year overall survival for in situ and infiltrative i-ALCL was 100% and 52.5%, respectively. CONCLUSIONS In situ i-ALCLs have an indolent clinical course and generally remain free of disease after implant removal. However, infiltrative i-ALCLs could have a more aggressive clinical course that might require additional therapy to implant removal.
Collapse
Affiliation(s)
- C Laurent
- Department of Pathology, Institut Universitaire du Cancer-Oncopole, Toulouse INSERM, U.1037, Centre de recherche en cancérologie de Toulouse-Purpan, Toulouse
| | - A Delas
- Department of Pathology, Institut Universitaire du Cancer-Oncopole, Toulouse
| | - P Gaulard
- Department of Pathology, AP-HP, Groupe hospitalier Henri Mondor-Albert Chenevier, Créteil INSERM U955, Université Paris-Est, Créteil
| | - C Haioun
- INSERM U955, Université Paris-Est, Créteil Lymphoid Malignancies Unit, AP-HP, Groupe hospitalier Henri Mondor-Albert Chenevier, Créteil
| | - A Moreau
- Department of Pathology, Centre Hospitalier Hôtel Dieu, Nantes
| | - L Xerri
- Department of Pathology, Institut Paoli-Calmettes, Marseille
| | | | - T Rousset
- Department of Pathology, Hôpital Gui de Chauliac-Saint Eloi, Montpellier
| | - I Quintin-Roue
- Department of Pathology, Centre Hospitalier de Brest, Brest, France
| | - T Petrella
- Département de Pathologie, Montréal, Canada
| | - J F Emile
- Department of Pathology, Hôpital Ambroise Paré, Boulogne
| | - N Amara
- Department of Pathology, Institut Universitaire du Cancer-Oncopole, Toulouse
| | - P Rochaix
- Department of Pathology, Institut Universitaire du Cancer-Oncopole, Toulouse
| | | | - A M Tasei
- Department of Pathology, Centre Hospitalier Henri Duffaut, Avignon
| | - E Menet
- Department of Pathology, Hôpital René Huguenin, Saint Cloud
| | | | - V Costes
- Department of Pathology, Hôpital Gui de Chauliac-Saint Eloi, Montpellier
| | | | - J F Michiels
- Department of Pathology, Centre Hospitalier Pasteur L'Archet, Nice
| | | | - L de Leval
- Pathology institut of Lausanne, Centre Hospitalier Universitaire Vaudois, Suisse, Lausanne, Switzerland
| | - P Brousset
- Department of Pathology, Institut Universitaire du Cancer-Oncopole, Toulouse INSERM, U.1037, Centre de recherche en cancérologie de Toulouse-Purpan, Toulouse
| | - G Delsol
- Department of Pathology, Institut Universitaire du Cancer-Oncopole, Toulouse INSERM, U.1037, Centre de recherche en cancérologie de Toulouse-Purpan, Toulouse
| | - L Lamant
- Department of Pathology, Institut Universitaire du Cancer-Oncopole, Toulouse INSERM, U.1037, Centre de recherche en cancérologie de Toulouse-Purpan, Toulouse
| |
Collapse
|
14
|
de Leval L, Bonnet C, Copie-Bergman C, Seidel L, Baia M, Brière J, Molina TJ, Fabiani B, Petrella T, Bosq J, Gisselbrecht C, Siebert R, Tilly H, Haioun C, Fillet G, Gaulard P. Diffuse large B-cell lymphoma of Waldeyer's ring has distinct clinicopathologic features: a GELA study. Ann Oncol 2012; 23:3143-3151. [PMID: 22700993 DOI: 10.1093/annonc/mds150] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/06/2023] Open
Abstract
BACKGROUND Diffuse large B-cell lymphomas (DLBCLs) arising in specific extranodal sites have peculiar clinicopathologic features. PATIENTS AND METHODS We analyzed a cohort of 187 primary Waldeyer's ring (WR) DLBCLs retrieved from GELA protocols using anthracyclin-based polychemotherapy. RESULTS Most patients (92%) had stage I-II disease. A germinal center B-cell-like (GCB) immunophenotype was observed in 61%, and BCL2 expression in 55%, of WR DLBCLs. BCL2, BCL6, IRF4 and MYC breakpoints were observed in, respectively, 3 of 42 (7%), 9 of 36 (25%), 2 of 26 (8%) and 4 of 40 (10%) contributive cases. A variable follicular pattern was evidenced in 30 of 68 (44%) large biopsy specimens. The 5-year progression-free survival (PFS) and the overall survival (OS) of 153 WR DLBCL patients with survival information were 69.5% and 77.8%, respectively. The GCB immunophenotype correlated with a better OS (P = 0.0015), while BCL2 expression predicted a worse OS (P = 0.037), an effect overcome by the GCB/non-GCB classification. Compared with matched nodal DLBCLs, WR DLBCLs with no age-adjusted international prognostic index factor disclosed a better 5-year PFS rate (77.5% versus 70.7%; P = 0.03). CONCLUSIONS WR DLBCLs display distinct clinicopathologic features compared with conventional DLBCLs, with usual localized-stage disease, common follicular features and a high frequency of GCB immunophenotype contrasting with a low rate of BCL2 rearrangements. In addition, they seem to be associated with a better outcome than their nodal counterpart.
Collapse
Affiliation(s)
- L de Leval
- Department of Laboratories, Institute of Pathology, C.H.U.V. Lausanne, Lausanne, Switzerland.
| | - C Bonnet
- Department of Clinical Hematology, C.H.U. of Liège, Liège, Belgium
| | - C Copie-Bergman
- Lymphoid Malignancies Unit, Henri-Mondor Hospital, AP-HP, Créteil; INSERM U955, Henri-Mondor Hospital, Créteil; Department of Medicine, Paris-Est University, Créteil, France
| | - L Seidel
- Department of Biostatistics, Liège University, Liège, Belgium
| | - M Baia
- Lymphoid Malignancies Unit, Henri-Mondor Hospital, AP-HP, Créteil; INSERM U955, Henri-Mondor Hospital, Créteil
| | - J Brière
- INSERM U728, Saint-Louis Hospital, Paris; Department of Pathology, Saint Louis Hospital, AP-HP, Paris
| | - T J Molina
- Department of Pathology, Hôtel-Dieu Hospital, AP-HP, Paris Descartes University, Paris
| | - B Fabiani
- Department of Pathology, Saint-Antoine Hospital, Paris
| | | | - J Bosq
- Department of Biopathology, Morpological Unit, Gustave Roussy Institute, Villejuif, France
| | | | - R Siebert
- Institute of Human Genetics, Christian-Albrechts-University, Kiel; University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - H Tilly
- Department of Hematology, UMR918, Henri Becquerel Center, Rouen University, Rouen, France
| | - C Haioun
- Lymphoid Malignancies Unit, Henri-Mondor Hospital, AP-HP, Créteil; INSERM U955, Henri-Mondor Hospital, Créteil; Department of Medicine, Paris-Est University, Créteil, France
| | - G Fillet
- Department of Clinical Hematology, C.H.U. of Liège, Liège, Belgium
| | - P Gaulard
- Lymphoid Malignancies Unit, Henri-Mondor Hospital, AP-HP, Créteil; INSERM U955, Henri-Mondor Hospital, Créteil; Department of Medicine, Paris-Est University, Créteil, France
| |
Collapse
|
15
|
Sook M, Hamoir E, de Leval L, Duquenne S, Larbuisson R, Joris J, Meurisse M, Defraigne J, Radermecker MA. Cardiac paraganglioma: diagnostic work up and review of the literature. Acta Chir Belg 2012; 112:310-313. [PMID: 23008998] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
Paraganglioma of the heart are potentially invasive, highly vascularized tumors for which complete resection may be curative. Derived from the cardiac wall in most instances, resectability can be assessed after integration of the data provided by MRI in T2 sequence, and coronarography. A fully documented case of a large cardiac pheochromocytoma of the left atrium and AV groove is reported and the pertinent literature on the subject is here presented.
Collapse
Affiliation(s)
- M Sook
- Department of Cardiovascular Surgery, University Hospital of Liège, Belgium
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Gaulard P, de Leval L. IN9 Pathology and pathophysiology of peripheral T-cell lymphomas. Crit Rev Oncol Hematol 2012. [DOI: 10.1016/s1040-8428(12)70023-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
17
|
Figiel S, de Leval L, Rousié C, Duysinx B, Louis R, Defraigne JO, Radermecker M. [Clinical case of the month. The "classic" triad presentation of mucinous bronchiolo-alveolar carcinoma]. Rev Med Liege 2010; 65:611-614. [PMID: 21189525] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
The case of a 59-year-old female complaining of cough of recent onset, abundant salty expectoration and lung condensation is presented. This "triad" constitutes a rare but nearly pathognomonic presentation of mucinous bronchioloalveolar carcinoma (BAC) of the lung.
Collapse
Affiliation(s)
- S Figiel
- Service de Chirurgie Cardio-Vasculaire, Université de Liège, Belgique.
| | | | | | | | | | | | | |
Collapse
|
18
|
Hamoudi RA, Appert A, Ye H, Ruskone-Fourmestraux A, Streubel B, Chott A, Raderer M, Gong L, Wlodarska I, De Wolf-Peeters C, MacLennan KA, de Leval L, Isaacson PG, Du MQ. Differential expression of NF-kappaB target genes in MALT lymphoma with and without chromosome translocation: insights into molecular mechanism. Leukemia 2010; 24:1487-97. [PMID: 20520640 DOI: 10.1038/leu.2010.118] [Citation(s) in RCA: 78] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Mucosa-associated lymphoid tissue (MALT) lymphoma is characterized by t(11;18)(q21;q21)/API2-MALT1, t(1;14)(p22;q32)/BCL10-IGH and t(14;18)(q32;q21)/IGH-MALT1, which commonly activate the nuclear factor (NF)-kappaB pathway. Gastric MALT lymphomas harboring such translocations usually do not respond to Helicobacter pylori eradication, while most of those without translocation can be cured by antibiotics. To understand the molecular mechanism of these different MALT lymphoma subgroups, we performed gene expression profiling analysis of 21 MALT lymphomas (13 translocation-positive, 8 translocation-negative). Gene set enrichment analysis (GSEA) of the NF-kappaB target genes and 4394 additional gene sets covering various cellular pathways, biological processes and molecular functions have shown that translocation-positive MALT lymphomas are characterized by an enhanced expression of NF-kappaB target genes, particularly toll like receptor (TLR)6, chemokine, CC motif, receptor (CCR)2, cluster of differentiation (CD)69 and B-cell CLL/lymphoma (BCL)2, while translocation-negative cases were featured by active inflammatory and immune responses, such as interleukin-8, CD86, CD28 and inducible T-cell costimulator (ICOS). Separate analyses of the genes differentially expressed between translocation-positive and -negative cases and measurement of gene ontology term in these differentially expressed genes by hypergeometric test reinforced the above findings by GSEA. Finally, expression of TLR6, in the presence of TLR2, enhanced both API2-MALT1 and BCL10-mediated NF-kappaB activation in vitro. Our findings provide novel insights into the molecular mechanism of MALT lymphomas with and without translocation, potentially explaining their different clinical behaviors.
Collapse
Affiliation(s)
- R A Hamoudi
- Department of Pathology, University of Cambridge, Cambridge, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Delfosse V, de Leval L, De Roover A, Delwaide J, Honoré P, Boniver J, Detry O. Budd-Chiari syndrome complicating hepatic sarcoidosis: definitive treatment by liver transplantation: a case report. Transplant Proc 2010; 41:3432-4. [PMID: 19857764 DOI: 10.1016/j.transproceed.2009.09.021] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Sarcoidotic involvement of the liver is frequent, albeit uncommonly symptomatic. Severe complications are rare, but may seldom require liver transplantation. Budd-Chiari syndrome has been described in a few patients with hepatic sarcoidosis. Herein we have reported the case of a young woman suffering from hepatic sarcoidosis who developed severe cholestasis and chronic Budd-Chiari syndrome. She successfully underwent orthotopic liver transplantation (OLT) and is asymptomatic with normal liver function at 3 years follow-up. Histopathological assessment of the liver explant demonstrated a florid granulomatous process, with involvement of the large intrahepatic veins, providing an anatomical basis for the vascular flow disturbances. This case adds further evidence that liver transplantation may be the curative treatment for complicated sarcoidotic liver disease.
Collapse
Affiliation(s)
- V Delfosse
- Department of Pathology, CHU de Liège, University of Liège, B4000 Liège, Belgium
| | | | | | | | | | | | | |
Collapse
|
20
|
de Leval L. [Molecular classification of ganglionic T cell lymphomas. pathological and diagnostic implications]. Bull Mem Acad R Med Belg 2010; 165:99. [PMID: 21166134] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
|
21
|
Bonnet C, Beguin Y, Deprijck B, de Leval L, Fillet G. [Current treatment of follicular lymphoma]. Rev Med Suisse 2009; 5:1663-1667. [PMID: 19772198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
After diffuse large B-cell lymphoma, follicular lymphoma is the most frequent non-Hodgkin's lymphoma. It remains incurable, except for localized diseases. Advanced disease has to be treated only in the presence of clinical and/or biology aggressiveness. These patients should be treated by rituximab (Mab-Thera) associated to polychemotherapy comprising cyclophosphamide, vincristine and prednisone. After this therapy, the benefit of rituximab in maintenance has to be confirmed. Autologous stem cell transplantation is now reserved for young patients in first relapse. Allogenic stem cell transplantation is also an interesting option. The other therapeutic options comprise radio-immunotherapy with 90Y ibritumomab tiuxetan (Zevalin) and bortezomib (Velcade).
Collapse
MESH Headings
- Antibodies, Monoclonal/administration & dosage
- Antibodies, Monoclonal/therapeutic use
- Antibodies, Monoclonal, Murine-Derived
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Boronic Acids/administration & dosage
- Bortezomib
- Chemotherapy, Adjuvant
- Cyclophosphamide/administration & dosage
- Hematopoietic Stem Cell Transplantation
- Humans
- Lymphoma, Follicular/drug therapy
- Lymphoma, Follicular/radiotherapy
- Lymphoma, Follicular/therapy
- Prednisone/administration & dosage
- Prognosis
- Pyrazines/administration & dosage
- Radioimmunotherapy
- Radiotherapy, Adjuvant
- Risk Factors
- Rituximab
- Transplantation, Autologous
- Transplantation, Homologous
- Treatment Outcome
- Vincristine/administration & dosage
Collapse
Affiliation(s)
- C Bonnet
- Service d'hématologie clinique, CHU Sart-Tilman, 4000 Liège, Belgique
| | | | | | | | | |
Collapse
|
22
|
Willems E, Canivet JL, Ghaye B, de Leval L, Radermecker M, Preiser JC, Beguin Y. Pulmonary veno-occlusive disease in myeloproliferative disorder. Eur Respir J 2009; 33:213-6. [PMID: 19118232 DOI: 10.1183/09031936.00157707] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
The present study reports a case of biopsy-proven pulmonary veno-occlusive disease as a cause of severe pulmonary hypertension in a patient suffering from a chronic myeloproliferative disorder. The pulmonary disease evolved favourably under treatment with defibrotide, a pro-fibrinolytic medication used in hepatic veno-occlusive disease.
Collapse
Affiliation(s)
- E Willems
- Department of Medicine, Division of Haematology, University Hospital Centre, University of Liege, Domaine Universitaire du Sart-Tilman, Liege, Belgium
| | | | | | | | | | | | | |
Collapse
|
23
|
Bethlen S, Chandrikakumari K, Leval LD, Giot JB, Mukeba D, Leonard P, Frippiat F, Meuris C, Delwaide J, Moutschen M. Chronic hepatitis C infection in a patient with bone marrow hypoplasia. World J Gastroenterol 2008; 14:4238-40. [PMID: 18636673 PMCID: PMC2725389 DOI: 10.3748/wjg.14.4238] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Chronic hepatitis C virus (HCV) infection is associated with multifarious extra-hepatic manifestations; the most described and discussed being mixed cryoglobulinemia which is strongly related to B-cell lymphoproliferative disorders (LPDs). We present a case of chronic HCV infection and mixed cryoglobulinemia, with minimal liver involvement. The case is a 53-year-old patient who was diagnosed as having bone marrow hypoplasia at the age of three. She received several blood transfusions to normalize her haemoglobin. At the age of 31, she was diagnosed with rheumatoid arthritis on account of her diffuse joint pain and inflammation, elevated rheumatoid factor (RF) and Raynaud’s phenomenon. Twenty years later, monoclonal gammopathy of IgG Lambda (one year later, changed to IgM Kappa) was detected during a routine examination. A bone marrow biopsy showed hypoplasia, Kappa positive B-lymphocytes and low-grade malignant lymphoma cells. PCR of the bone marrow aspirate was not contributory. No treatment was initiated owing to her poor bone marrow function and she is under regular follow-up.
Collapse
|
24
|
Boudry C, Markine-Goriaynoff N, Delforge C, Springael JY, de Leval L, Drion P, Russell G, Haig DM, Vanderplasschen AF, Dewals B. The A5 gene of alcelaphine herpesvirus 1 encodes a constitutively active G-protein-coupled receptor that is non-essential for the induction of malignant catarrhal fever in rabbits. J Gen Virol 2008; 88:3224-3233. [PMID: 18024890 DOI: 10.1099/vir.0.83153-0] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Many gammaherpesviruses encode G-protein-coupled receptors (GPCRs). Several in vivo studies have revealed that gammaherpesvirus GPCRs are important for viral replication and for virus-induced pathogenesis. The gammaherpesvirus alcelaphine herpesvirus 1 (AlHV-1) is carried asymptomatically by wildebeest, but causes malignant catarrhal fever (MCF) following cross-species transmission to a variety of susceptible species. The A5 ORF of the AlHV-1 genome encodes a putative GPCR. In the present study, we investigated whether A5 encodes a functional GPCR and addressed its role in viral replication and in the pathogenesis of MCF. In silico analysis supported the hypothesis that A5 could encode a functional GPCR as its expression product contained several hallmark features of GPCRs. Expression of A5 as tagged proteins in various cell lines revealed that A5 localizes in cell membranes, including the plasma membrane. Using [35S]GTPgammaS and reporter gene assays, we found that A5 is able to constitutively couple to alpha i-type G-proteins in transfected cells, and that this interaction is able to inhibit forskolin-triggered cAMP response element-binding protein (CREB) activation. Finally, using an AlHV-1 BAC clone, we produced a strain deleted for A5 and a revertant strain. Interestingly, the strain deleted for A5 replicated comparably to the wild-type parental strain and induced MCF in rabbits that was indistinguishable from that of the parental strain. The present study is the first to investigate the role of an individual gene of AlHV-1 in MCF pathogenesis.
Collapse
Affiliation(s)
- C Boudry
- Immunology-Vaccinology (B43b), Department of Infectious and Parasitic Diseases, Faculty of Veterinary Medicine, University of Liège, B-4000 Liège, Belgium
| | - N Markine-Goriaynoff
- Immunology-Vaccinology (B43b), Department of Infectious and Parasitic Diseases, Faculty of Veterinary Medicine, University of Liège, B-4000 Liège, Belgium
| | - C Delforge
- Immunology-Vaccinology (B43b), Department of Infectious and Parasitic Diseases, Faculty of Veterinary Medicine, University of Liège, B-4000 Liège, Belgium
| | - J-Y Springael
- Institute of Interdisciplinary Research in Human and Molecular Biology (IRIBHM), Free University of Brussels, Erasme, 808 Route de Lennik, B-1070 Brussels, Belgium
| | - L de Leval
- Department of Pathology (B23), Faculty of Medicine, University of Liège, B-4000 Liège, Belgium
| | - P Drion
- Animal facility (B23), University of Liège, B-4000 Liège, Belgium
| | - G Russell
- Moredun Research Institute, Pentlands Science Park, Penicuik, Midlothian EH26 0PZ, UK
| | - D M Haig
- Moredun Research Institute, Pentlands Science Park, Penicuik, Midlothian EH26 0PZ, UK
| | - A F Vanderplasschen
- Immunology-Vaccinology (B43b), Department of Infectious and Parasitic Diseases, Faculty of Veterinary Medicine, University of Liège, B-4000 Liège, Belgium
| | - B Dewals
- Immunology-Vaccinology (B43b), Department of Infectious and Parasitic Diseases, Faculty of Veterinary Medicine, University of Liège, B-4000 Liège, Belgium
| |
Collapse
|
25
|
Cherdon C, Rolin S, Hanson J, Drion P, de Leval L, Defraigne J, Dogné J. BM-573, a thromboxane receptor antagonist, reduces development of atherosclerosis in apo E-deficient mice. J Mol Cell Cardiol 2007. [DOI: 10.1016/j.yjmcc.2007.03.095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
26
|
Dewals B, Boudry C, Gillet L, Markine-Goriaynoff N, de Leval L, Haig DM, Vanderplasschen A. Cloning of the genome of Alcelaphine herpesvirus 1 as an infectious and pathogenic bacterial artificial chromosome. J Gen Virol 2006; 87:509-517. [PMID: 16476972 DOI: 10.1099/vir.0.81465-0] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Alcelaphine herpesvirus 1 (AlHV-1), carried asymptomatically by wildebeest, causes malignant catarrhal fever (MCF) following cross-species transmission to a variety of susceptible species of the order Artiodactyla. The study of MCF pathogenesis has been impeded by an inability to produce recombinant virus, mainly due to the fact that AlHV-1 becomes attenuated during passage in culture. In this study, these difficulties were overcome by cloning the entire AlHV-1 genome as a stable, infectious and pathogenic bacterial artificial chromosome (BAC). A modified loxP-flanked BAC cassette was inserted in one of the two large non-coding regions of the AlHV-1 genome. This insertion allowed the production of an AlHV-1 BAC clone stably maintained in bacteria and able to regenerate virions when transfected into permissive cells. The loxP-flanked BAC cassette was excised from the genome of reconstituted virions by growing them in permissive cells stably expressing Cre recombinase. Importantly, BAC-derived AlHV-1 virions replicated comparably to the virulent (low-passage) AlHV-1 parental strain and induced MCF in rabbits that was indistinguishable from that of the virulent parental strain. The availability of the AlHV-1 BAC is an important advance for the study of MCF that will allow the identification of viral genes involved in MCF pathogenesis, as well as the production of attenuated recombinant candidate vaccines.
Collapse
Affiliation(s)
- B Dewals
- Department of Infectious and Parasitic Diseases, Immunology-Vaccinology (B43b), Faculty of Veterinary Medicine, University of Liège, B-4000 Liège, Belgium
| | - C Boudry
- Department of Infectious and Parasitic Diseases, Immunology-Vaccinology (B43b), Faculty of Veterinary Medicine, University of Liège, B-4000 Liège, Belgium
| | - L Gillet
- Department of Infectious and Parasitic Diseases, Immunology-Vaccinology (B43b), Faculty of Veterinary Medicine, University of Liège, B-4000 Liège, Belgium
| | - N Markine-Goriaynoff
- Department of Infectious and Parasitic Diseases, Immunology-Vaccinology (B43b), Faculty of Veterinary Medicine, University of Liège, B-4000 Liège, Belgium
| | - L de Leval
- Department of Pathology, Faculty of Medicine, University of Liège, B-4000 Liège, Belgium
| | - D M Haig
- The Moredun Research Institute, Pentlands Science Park, Bush Loan, Penicuik, Midlothian EH26 0PZ, UK
| | - A Vanderplasschen
- Department of Infectious and Parasitic Diseases, Immunology-Vaccinology (B43b), Faculty of Veterinary Medicine, University of Liège, B-4000 Liège, Belgium
| |
Collapse
|
27
|
Detry O, Léonard P, Delwaide J, de Leval L, Radermacher V, De Roover A, Meurisse M, Honoré P. [Laparoscopic liver resection of a hydatid cyst]. Rev Med Liege 2005; 60:700-2. [PMID: 16265963] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/05/2023]
Abstract
Most of the echinococcosis cases treated in Belgium are contracted in African and Mediterranean countries. In this paper the authors describe the case of a Mediterranean patient suffering from a hepatic hydatid cyst treated by oral albendazole and laparoscopic liver resection.
Collapse
Affiliation(s)
- O Detry
- Service de Chirurgie Abdominale et Transplantation, CHU Sart Tilman B35, B-4000 Liège
| | | | | | | | | | | | | | | |
Collapse
|
28
|
Trimeche M, Korbi S, Ziadi S, Amara K, Boniver J, de Leval L. [Molecular characterization of Epstein-Barr virus associated with classical Hodgkin's lymphoma in Tunisia: prevalence of the LMP1 oncogene deletions and A and B viruses strains]. Ann Biol Clin (Paris) 2005; 63:193-9. [PMID: 15771977] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2004] [Accepted: 01/07/2005] [Indexed: 05/02/2023]
Abstract
Epstein-Barr virus (EBV) is detected in Hodgkin's lymphoma (HL) at variable frequencies, depending on various factors including the geographic location. The prevalence of EBV is high among HL diagnosed in the region of the center of Tunisia. The aim of the current work was to define the genotypic features of EBV in a series of EBV-positive HL in this area, in comparison to those of EBV found in association with benign lymphoadenopathies. A 30 bp and a 69 bp deletion within the LMP1 gene were detected in 41% and 11% of HL cases, respectively. In reactive lymph nodes, the 30 bp deletion was found in 43% of the cases. Type A EBV was detected in 84% of HL cases and in 96% of reactive lymphoadenopathies, and type B EBV was detected in others. No significant association was found between histological type of HL, age of the patients, or stage at diagnosis, and the molecular configuration of LMP1. However, LMP1 deletions were found more frequently among male patients. The significance of these results is discussed.
Collapse
Affiliation(s)
- M Trimeche
- Laboratoire d'anatomie et de cytologie pathologiques, CHU Farhat Hached, Sousse, Tunisie
| | | | | | | | | | | |
Collapse
|
29
|
Quaniers J, Durieux R, de Leval L, Limet R. Abdominal aortic aneurysm due to Brucella melitensis. Acta Chir Belg 2005; 105:93-5. [PMID: 15790211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/02/2023]
Affiliation(s)
- J Quaniers
- Department of Cardiovascular Surgery, University of Liege Hospital, Liège, Belgium
| | | | | | | |
Collapse
|
30
|
Bonaventure S, Scagnol I, Linder JL, Fillet G, Boniver J, de Leval L. [Image of the month. Splenic cyst]. Rev Med Liege 2005; 60:5-6. [PMID: 15771309] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/02/2023]
Affiliation(s)
- S Bonaventure
- Service d'Anatomie et Cytologie Pathologiques, CHU Sart Tilman, Liège
| | | | | | | | | | | |
Collapse
|
31
|
|
32
|
|
33
|
Weber T, Broux R, Damas F, de Leval L, Boniver J, Hermans G. [Anatomo-clinical confrontation: idiopathic pulmonary fibrosis]. Rev Med Liege 2004; 59:430-4. [PMID: 15493155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/01/2023]
Abstract
Idiopathic pulmonary fibrosis and pulmonary fibrosis associated with systemic diseases are the most frequent diffuse interstitial pulmonary diseases. They slowly but irrevocably progress towards terminal respiratory failure. They can also be complicated by severe acute respiratory failure and admission in the intensive care unit can be discussed. Despite invasive mechanical ventilation, anti-infectious and immunosuppressive treatments, the disease carries a high mortality rate. We report and discuss the case of a patient with idiopathic, pulmonary fibrosis (UIP) who underwent rapid clinical deterioration.
Collapse
Affiliation(s)
- T Weber
- Service de Pneumologie, CHR Citadelle, Liège
| | | | | | | | | | | |
Collapse
|
34
|
deRoover A, de Leval L, Gilmaire J, Detry O, Boniver J, Honoré P, Meurisse M. A new model for human intestinal preservation: comparison of University of Wisconsin and Celsior preservation solutions. Transplant Proc 2004; 36:270-2. [PMID: 15050131 DOI: 10.1016/j.transproceed.2003.12.003] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
AIM We compared University of Wisconsin (UW) and Celsior preservation solutions using a new model of human intestinal preservation that mimics the clinical conditions of small bowel procurement. METHODS Intestinal grafts were harvested from four multiorgan donors. After classic warm dissection for organ procurement, an ileal segment of 50 cm was immediately flushed with Celsior. After the perfusion of the abdominal organs with UW, a second segment of adjacent ileum was harvested. The two intestinal grafts were then divided into segments by stapling, before immersion into the corresponding preservation solution (Celsior or UW) for 0-, 6-, 12-, or 24-hour incubation at 4 degrees C. A histological score was graded after blinded examination of three random specimens within each ileal graft for each duration of preservation. RESULTS Control specimens showed normal histology. After 6 hours of preservation, most villi showed complete epithelial detachment although the crypts appeared intact. After 12 hours of preservation, a larger proportion of the villi showed extensive epithelial sloughing. After 24 hours, the damage involved the entire mucosa with the crypt epithelium largely detached from the basal membrane. No statistical difference in histological score was observed between the two preservation solutions. CONCLUSION This study showed severe histological alterations of graft mucosa after short periods of preservation by UW or Celsior solutions. This model may be useful to evaluate improvements in the quality of preservation of human intestinal transplants.
Collapse
Affiliation(s)
- A deRoover
- Departments of Transplantation and Pathology, Centre Hospitalier Universitaire, Liège, Belgium.
| | | | | | | | | | | | | |
Collapse
|
35
|
Polus M, Piront P, Jerusalem G, Sautois B, Defechereux T, de Leval L, Fillet G. [Image of the month. Merkel cell tumor: response to chemotherapy]. Rev Med Liege 2004; 59:67-8. [PMID: 15112893] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/29/2023]
Affiliation(s)
- M Polus
- Université de Liège, Service d'Oncologie médicale
| | | | | | | | | | | | | |
Collapse
|
36
|
Abstract
Diffuse large B-cell lymphoma (DLBCL), the single largest category of lymphoma, is a clinically and biologically heterogeneous disease entity. Clinically, patients differ in their mode of presentation and respond variably to therapy. A combination of clinical parameters can be used to predict the patient's response to therapy and survival. The pathological variability of DLBCL is expressed in morphology, immunophenotype, cytogenetic and molecular genetic features. Numerous markers detectable by immunohistochemistry and linked to different aspects of tumour biology have been studied in DLBCL, including lineage-associated and immune markers, proliferation and apoptosis markers, cell adhesion molecules, and more recently stage-specific markers of B-cell differentiation. This review summarizes these studies in regard to their clinical significance and in the light of recent advances in our understanding of the molecular pathology and histogenesis of DLBCL.
Collapse
Affiliation(s)
- L de Leval
- Department of Pathology, C.H.U. of Liège, Belgium.
| | | |
Collapse
|
37
|
Abstract
The NF-kappaB2/p100 and bcl-3 genes are involved in chromosomal translocations described in chronic lymphocytic leukemias (CLL) and non-Hodgkin's lymphomas, and nuclear factor kappaB (NF-kappaB) protects cancer cells against apoptosis. Therefore, we investigated whether this transcription factor could modulate the expression of the Bcl-2 antiapoptotic protein. Bcl-2 promoter analysis showed multiple putative NF-kappaB binding sites. Transfection assays of bcl-2 promoter constructs in HCT116 cells showed that NF-kappaB can indeed transactivate bcl-2. We identified a kappaB site located at position -180 that can only be bound and transactivated by p50 or p52 homodimers. As p50 and p52 homodimers are devoid of any transactivating domains, we showed that they can transactivate the bcl-2 promoter through association with Bcl-3. We also observed that stable overexpression of p100 and its processed product p52 can induce endogenous Bcl-2 expression in MCF7AZ breast cancer cells. Finally, we demonstrated that, in breast cancer and leukemic cells (CLL), high NF-kappaB2/p100 expression was associated with high Bcl-2 expression. Our data suggest that Bcl-2 could be an in vivo target gene for NF-kappaB2/p100.
Collapse
Affiliation(s)
- P Viatour
- Center for Cellular and Molecular Therapy, University of Liège, Liège, Belgium
| | | | | | | | | | | | | |
Collapse
|
38
|
Mutijima E, Martinez C, Boniver J, de Leval L. [Image of the month. Myocardial rupture]. Rev Med Liege 2003; 58:4-6. [PMID: 12647590] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 03/01/2023]
Affiliation(s)
- E Mutijima
- Université de Liège, Département d'Anatomie Pathologique
| | | | | | | |
Collapse
|
39
|
Delbecque K, Radermecker M, Léonard P, Moutschen M, Hermans G, Boniver J, de Leval L. [Image of the month. Pulmonary malacoplakia due to Rhodococcus equi in a patient with AIDS]. Rev Med Liege 2002; 57:685-7. [PMID: 12564097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/28/2023]
Affiliation(s)
- K Delbecque
- Chercheur Qualifié au FNRS, Service d'Anatomie Pathologique
| | | | | | | | | | | | | |
Collapse
|
40
|
Malaise MG, Kaye O, Radermecker M, Duysinx B, Hustinx R, Hermans G, de Leval L. [Chronic thoracic pain]. Rev Med Liege 2002; 57:270-3. [PMID: 12143167] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
Abstract
The etiological diagnosis of chronic thoracic pain is wide, from benign mechanical disorders to tumors. Reaching the exact diagnosis in often time consuming. Despite the availability of new techniques of imagery, a meticulous clinical history and physical examination remain mandatory. They will lead the exploration. Idiopathic intercostal neuralgia does not exist.
Collapse
Affiliation(s)
- M G Malaise
- Service de Rhumatologie, Département de Médecine Interne, CHU Sart Tilman
| | | | | | | | | | | | | |
Collapse
|
41
|
Andrianne R, Detroz B, Delbecque K, Leduc F, Szapiro D, Boniver J, de Leval L. [Anatomic-clinical confrontation. Large pelvic mass in a young man]. Rev Med Liege 2002; 57:148-54. [PMID: 12014262] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
Abstract
The authors report the case of a gastro-intestinal stromal tumor (GIST) with unusual clinico-pathological features, presenting as a large cystic rectal mass in a young man. The differential diagnosis of pelvic masses is discussed. In light of this case, the recent literature related to the pathogenesis, diagnosis and treatment of GIST is reviewed.
Collapse
Affiliation(s)
- R Andrianne
- Département d'Anatomie Pathologique, CHU Sart Tilman
| | | | | | | | | | | | | |
Collapse
|
42
|
Husson H, Carideo EG, Cardoso AA, Lugli SM, Neuberg D, Munoz O, de Leval L, Schultze J, Freedman AS. MCP-1 modulates chemotaxis by follicular lymphoma cells. Br J Haematol 2001; 115:554-62. [PMID: 11736935 DOI: 10.1046/j.1365-2141.2001.03145.x] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
The localization and establishment of follicular lymphoma (FL) cells in distinct anatomic sites probably involves chemokine and adhesion receptors on the neoplastic cells and appropriate chemokines and adhesion receptor ligands in the microenvironment. Several chemokines play an important role in normal B-cell trafficking and differentiation. Monocyte chemoattractant protein-1 (MCP-1) is a C-C chemokine that induces chemotaxis of a variety of lymphoid cells through its receptor CCR2. CCR2 is also expressed on B cells, and MCP-1 induces chemotaxis of normal B cells. In this report, we investigated expression and function of CCR2 on FL cells. We found FL cells as well as the t(14; 18)+ B-cell lymphoma line H2 expressed CCR2. MCP-1 potentiated SDF-1-induced chemotaxis of FL cells and H2 cells, but MCP-1 alone did not induce chemotaxis. The specificity of the effects of MCP-1 and SDF-1 was demonstrated by antibody blocking studies. Because FL cells are generally associated with follicular dendritic cells (FDCs), FDCs may be an important source of chemokines. We found that cultured FDCs produced MCP-1, and this production was enhanced by tumour necrosis factor. These data implicate MCP-1 in the migration and localization of FL cells.
Collapse
MESH Headings
- Antibodies, Monoclonal/pharmacology
- Cell Line
- Chemokine CCL2/immunology
- Chemokine CCL2/pharmacology
- Chemokine CXCL12
- Chemokines, CXC/immunology
- Chemokines, CXC/pharmacology
- Chemotaxis, Leukocyte/drug effects
- Chromosomes, Human, Pair 14
- Chromosomes, Human, Pair 18
- Dendritic Cells, Follicular/metabolism
- Drug Synergism
- Flow Cytometry/methods
- Humans
- Lymphoma, B-Cell
- Lymphoma, Follicular/immunology
- Lymphoma, Follicular/metabolism
- Receptors, CCR2
- Receptors, Chemokine/analysis
- Receptors, Chemokine/metabolism
- Reverse Transcriptase Polymerase Chain Reaction
- Translocation, Genetic
- Tumor Necrosis Factor-alpha/pharmacology
Collapse
Affiliation(s)
- H Husson
- Department of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
43
|
De Roover A, Detry O, Honoré P, Delbecque K, de Leval L, Delwaide J, Joris J, Canivet JL, Damas P, Boniver J, Lamy M, Meurisse M, Jacquet N. [Alpha-1-antitrypsin deficiency. An indication for pediatric liver transplantation]. Rev Med Liege 2001; 56:753-8. [PMID: 11789388] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
Alpha-1-antitrypsin deficiency is the most common inborn error of metabolism leading to liver transplantation, and the second cause of liver transplantation in children after biliary atresia. The authors report the case of a 6-year-old girl, who was suffering from end-stage liver disease secondary to alpha-1-antitrypsin deficiency. She was successfully treated by whole liver transplantation, the hepatic graft coming from a 3-year-old donor. Three months later she went back to school. The authors discuss the pathogenesis and the natural history of this frequent cause of liver transplantation in children.
Collapse
Affiliation(s)
- A De Roover
- Service de Chirurgie Abdominale et Transplantation, Université de Liège
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Waltregny D, de Leval L, Coppens L, Youssef E, de Leval J, Castronovo V. Detection of the 67-kD laminin receptor in prostate cancer biopsies as a predictor of recurrence after radical prostatectomy. Eur Urol 2001; 40:495-503. [PMID: 11752855 DOI: 10.1159/000049825] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
OBJECTIVES Reliable prognostic indicators are needed for a better pretherapeutic assessment of the agressiveness of organ-confined prostate cancer (PC) lesions. The 67-kD laminin receptor (67LR) is a cell-surface-associated protein involved in the acquisition of the invasive and metastatic phenotype of a variety of human cancer cell types. We have previously shown that 67LR detection in PC tissues from radical prostatectomy (RP) specimens is an independent predictor of biochemical (PSA) relapse in patients with clinically localized PC. In this study, we assessed 67LR detection in diagnostic PC biopsies as a predictor of biochemical relapse after RP. METHODS Diagnostic biopsy and subsequent RP tissue specimens from 151 patients with clinically localized PC were immunohistochemically analyzed for 67LR expression. The level of 67LR expression was evaluated by both intensity and extent of the staining. Clinicopathological preoperative and postoperative parameters, including 67LR expression, were correlated with each other and tested as predictors of biochemical relapse. RESULTS 67LR was detected in 67.5 and 68.2% of biopsies and RPs, respectively. 67LR detection in RP specimens was an independent predictor of relapse. The level of 67LR expression in the biopsy was significantly associated with the biopsy Gleason score (p<0.05) but failed to predict the pathological stage (p>0.1). Biochemical progression-free estimates for patients whose biopsy did or did not express the protein differed with only borderline statistical significance (p = 0.05). Multivariate analysis identified biopsy Gleason score as the only independent preoperative predictor of recurrence. Significant discrepancies in levels of 67LR expression were found between matched biopsy and RP specimens (p<0.05), with exact agreement rates <40%. CONCLUSIONS 67LR detection in PC biopsies was not a significant preoperative predictor of outcome after RP. Heterogeneity of 67LR expression and biopsy sampling errors most likely represented the main reasons for discordant results between biopsy and RP specimens.
Collapse
Affiliation(s)
- D Waltregny
- Metastasis Research Laboratory, University of Liège, Belgium.
| | | | | | | | | | | |
Collapse
|
45
|
de Leval L, Ferry JA, Falini B, Shipp M, Harris NL. Expression of bcl-6 and CD10 in primary mediastinal large B-cell lymphoma: evidence for derivation from germinal center B cells? Am J Surg Pathol 2001; 25:1277-82. [PMID: 11688462 DOI: 10.1097/00000478-200110000-00008] [Citation(s) in RCA: 72] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Primary mediastinal large B-cell lymphomas (LBCLs) constitute a unique subtype of diffuse LBCLs, with distinct clinical, immunophenotypic, and morphologic features. These lymphomas are thought to originate from the thymus, and it has been hypothesized that they derive from a population of B lymphocytes normally present in the thymic medulla. Most diffuse LBCLs harbor somatic mutations in their immunoglobulin genes, suggesting that they have been exposed to the germinal center. To investigate the possible relationship of mediastinal LBCLs to germinal center B cells, we analyzed the expression of bcl-6 and CD10 in 19 mediastinal LBCLs, using an immunoperoxidase technique on formalin-fixed tissue. We found that 19 of 19 (100%) mediastinal LBCLs were bcl-6+ and 6 of 19 (32%) mediastinal LBCLs were CD10+. Because mediastinal LBCLs usually lack BCL-6 gene rearrangement or mutations, expression of bcl-6 and CD10 in these tumors tends to support a germinal center derivation.
Collapse
Affiliation(s)
- L de Leval
- Department of Pathology, Massachusetts General Hospital, Boston 02114, USA
| | | | | | | | | |
Collapse
|
46
|
de Leval L, Harris NL, Longtine J, Ferry JA, Duncan LM. Cutaneous b-cell lymphomas of follicular and marginal zone types: use of Bcl-6, CD10, Bcl-2, and CD21 in differential diagnosis and classification. Am J Surg Pathol 2001; 25:732-41. [PMID: 11395550 DOI: 10.1097/00000478-200106000-00004] [Citation(s) in RCA: 111] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Cutaneous follicular lymphomas (FLs) and cutaneous B-cell lymphomas of extranodal marginal zone (MZL)/mucosal-associated lymphoid tissue (MALT) type may have morphologic overlap, despite the fact that they are thought to be of distinct derivation (germinal center vs. postgerminal center). The problem is compounded by the reported absence of bcl-2 expression by many cutaneous FLs, leading to speculation that cutaneous FL may be unrelated to nodal FL. The authors analyzed the expression of the germinal center-associated antigens bcl-6 and CD10 and of bcl-2 in 18 cutaneous B-cell lymphomas (10 FLs and eight MZLs), in relationship to CD21+ follicular structures, to clarify the relationship of nodal to cutaneous FLs and to explore the value of these antigens in differential diagnosis. The authors studied 10 cutaneous FLs (seven primary and three secondary) and eight MZLs (six primary and two secondary). The FLs (found in six men and four women age 45-75 years) involved the trunk (n = 3) and scalp, face and neck (n = 7). The MZLs (found in five women and three men age 34-81 years) involved the trunk (n = 4), face and neck (n = 2), and arm (n = 2). Immunostaining for CD21, bcl-6, CD10, and bcl-2 allowed the delineation of compartments within the tumors and yielded distinct patterns of staining in FL and MZL. In both follicular and interfollicular/diffuse areas of FL the neoplastic cells were bcl-6+ (10 of 10), often CD10+ (seven of 10, four of seven primary), and bcl-2+ (nine of 10, six of seven primary). Only three of seven cases (one of five primary) had bcl-2 rearrangement detectable by polymerase chain reaction. In the MZLs, the neoplastic B-cells were bcl-6-, CD10-, and bcl-2+ (eight of eight). Three patterns of CD21+ follicles were identified in MZL: reactive germinal centers, uniformly bcl-6+, CD10+, and bcl-2- (five of eight MZLs); colonized follicles, both bcl-6-, bcl-2+, and L26+ cells, and bcl-6+ and bcl-2- cells (five of eight MZLs); and expanded/colonized follicular dendritic cell meshworks, bcl-6- and bcl-2+ B cells with rare residual bcl-6+ and bcl-2- cells (four of eight MZLs). The authors conclude that cutaneous FLs express bcl-6 uniformly, usually express CD10 and bcl-2, and have a follicular pattern similar to nodal FL and consistent with a germinal center origin. The immunophenotype of cutaneous FL is distinct from that of cutaneous MZL, which is negative for bcl-6 and CD10. Colonized follicles in MZL, identified by CD21+ follicular dendritic cell meshworks, contained numerous bcl-6- and bcl-2+ B cells, and were readily distinguished from neoplastic follicles in FL. Conversely, CD21- interfollicular and diffuse areas in FLs contained bcl-6+ and CD10+ cells, which were not seen in diffuse areas of MZLs. Thus, the combination of bcl-2, bcl-6, and CD21 staining is useful for the distinction of cutaneous MZL from cutaneous FL.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- DNA-Binding Proteins/analysis
- Diagnosis, Differential
- Female
- Humans
- Lymphoma, B-Cell/pathology
- Lymphoma, B-Cell, Marginal Zone/chemistry
- Lymphoma, B-Cell, Marginal Zone/pathology
- Lymphoma, Follicular/chemistry
- Lymphoma, Follicular/pathology
- Male
- Middle Aged
- Neprilysin/analysis
- Proto-Oncogene Proteins/analysis
- Proto-Oncogene Proteins c-bcl-2/analysis
- Proto-Oncogene Proteins c-bcl-6
- Receptors, Complement 3d/analysis
- Skin Neoplasms/chemistry
- Skin Neoplasms/pathology
- Transcription Factors/analysis
- Zinc Fingers
Collapse
Affiliation(s)
- L de Leval
- Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA
| | | | | | | | | |
Collapse
|
47
|
Abstract
A truly follicular pattern is thought to be restricted to B-cell lymphomas. We observed a prominent follicular growth pattern in three cases of nodal peripheral T-cell lymphomas, of which two were initially diagnosed as follicular lymphomas. All three patients were male, ranged in age from 50 to 70 years, and had generalized lymphadenopathy at the time of diagnosis. The follicles were sharply demarcated in two cases and large and vague in one case; in all cases, they contained abundant follicular dendritic cells. Neoplastic cells were small to medium, with irregular cleaved or round nuclei and clear cytoplasm, which was abundant in one case. Lymphoma cells in all cases were CD4+ CD8- CD57- bcl-6, with CD10 coexpression in 2 cases. Clonal rearrangement of the gamma chain of the T-cell receptor gene was demonstrated in each case. These cases expand the differential diagnosis of lymphomas with a follicular growth pattern and suggest that neoplastic T cells may have the capacity to induce or home to follicular structures.
Collapse
MESH Headings
- Antigens, Neoplasm/metabolism
- Biomarkers, Tumor/metabolism
- CD4 Antigens/metabolism
- CD8 Antigens/metabolism
- Clone Cells
- DNA, Neoplasm/analysis
- DNA-Binding Proteins/metabolism
- Dendritic Cells/metabolism
- Dendritic Cells/pathology
- Diagnosis, Differential
- Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor
- Humans
- Immunoenzyme Techniques
- Lymph Nodes/metabolism
- Lymph Nodes/pathology
- Lymphoma, Follicular/genetics
- Lymphoma, Follicular/immunology
- Lymphoma, Follicular/metabolism
- Lymphoma, Follicular/pathology
- Lymphoma, T-Cell, Peripheral/genetics
- Lymphoma, T-Cell, Peripheral/immunology
- Lymphoma, T-Cell, Peripheral/metabolism
- Lymphoma, T-Cell, Peripheral/pathology
- Male
- Middle Aged
- Neoplasm Staging
- Neprilysin/metabolism
- Phenotype
- Proto-Oncogene Proteins/metabolism
- Proto-Oncogene Proteins c-bcl-6
- Transcription Factors/metabolism
Collapse
Affiliation(s)
- L de Leval
- Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
| | | | | | | | | |
Collapse
|
48
|
Deprez M, D'Hooghe M, Misson JP, de Leval L, Ceuterick C, Reznik M, Martin JJ, D'Hooge M. Infantile and juvenile presentations of Alexander's disease: a report of two cases. Acta Neurol Scand 1999; 99:158-65. [PMID: 10100959 DOI: 10.1111/j.1600-0404.1999.tb07338.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
We describe 2 new cases of Alexander's disease, the first to be reported in Belgium. The first patient, a 4-year-old girl, presented with progressive megalencephaly, mental retardation, spastic tetraparesis, ataxia and epilepsy: post-mortem examination showed widespread myelin loss with Rosenthal fibers (RFs) accumulation throughout the neuraxis. She was the third of heterozygotic twins, the 2 others having developed normally and being alive at age 5 years. The second patient developed at age 10 years and over a decade spastic paraparesis, palatal myoclonus, nystagmus, thoracic hyperkyphosis and thoraco-lumbar scoliosis with radiological findings of bilateral anterior leukoencephalopathy. Brain stereotactic biopsy at age 16 years demonstrated numerous RFs. With these 2 cases, we review the literature on the various clinico-pathological conditions reported as Alexander's disease. We discuss the nosology of this entity and the pathogeny of RFs formation and dysmyelination. Clues to the diagnosis of this encephalopathy in the living patient are briefly described.
Collapse
Affiliation(s)
- M Deprez
- Laboratory of Neuropathology, CHU University of Liège, Belgium
| | | | | | | | | | | | | | | |
Collapse
|
49
|
Boniver V, de Leval L, Daenen G, Honoré P, Davin C, Hardy N, Boniver J. [Anatomo-clinical correlation. A case of invasive pulmonary aspergillosis]. Rev Med Liege 1998; 53:592-6. [PMID: 9857753] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
This report describes a case of invasive pulmonary aspergillosis affecting a young female patient who had benefited from a liver transplantation for a fulminant hepatic failure. Infections following liver transplantation can happen but in this case the short delay to the fatal outcome is unusual (6 days). Corticotherapy given prior to transplantation could have impaired the immune system. The authors discuss the infections due to Aspergillus species and particularly invasive pulmonary aspergillosis.
Collapse
Affiliation(s)
- V Boniver
- Université de Liège, Service d'Anatomie pathologique
| | | | | | | | | | | | | |
Collapse
|
50
|
de Leval L, Colombi S, Debrus S, Demoitié MA, Greimers R, Linsley P, Moutschen M, Boniver J. CD28-B7 costimulatory blockade by CTLA4Ig delays the development of retrovirus-induced murine AIDS. J Virol 1998; 72:5285-90. [PMID: 9573306 PMCID: PMC110124 DOI: 10.1128/jvi.72.6.5285-5290.1998] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Mouse AIDS (MAIDS) induced in C57BL/6 mice by infection with a replication-defective retrovirus (Du5H) combines extensive lymphoproliferation and profound immunodeficiency. Although B cells are the main target of viral infection, recent research has focused on CD4(+) T cells, the activation of which is a key event in MAIDS induction and progression. A preliminary observation of increased expression of B7 molecules on B cells in MAIDS prompted us to address the possible involvement of the CD28/B7 costimulatory pathway in MAIDS. Mice infected with the MAIDS-inducing viral preparation were treated with murine fusion protein CTLA4Ig (3 x 50 microg/week given intraperitoneally), a competitive inhibitor of physiological CD28-B7 interactions. In CTLA4Ig-treated animals, the onset of the disease was delayed, lymphoproliferation progressed at a much slower rate than in untreated mice, and the loss of in vitro responsiveness to mitogens was reduced. Relative expression of Du5H did not differ between treated and untreated animals. These results suggest that the CD28/B7 costimulatory pathway contributes to MAIDS development.
Collapse
Affiliation(s)
- L de Leval
- Laboratory of Pathology, University of Liège, Liège, Belgium.
| | | | | | | | | | | | | | | |
Collapse
|